Fig. 4: Chemosensitivity of patients and corresponding PDX.

Imaging of target lesions in patients before chemotherapy (pre-treatment) and at the time specified post treatment. Tumor volumes for the corresponding PDX models were graphed as a function of days post-start of drug treatment. a UCC03: FDG PET/CT scan after two cycles of gemcitabine/carboplatin (Gem/Carbo) chemotherapy demonstrated decreased radiopharmaceutical accumulation in left iliac metastasis (partial response according to RECIST). Mice bearing the UCC03 PDX were randomized and treated with Gem/Carbo, gemcitabine, carboplatin or vehicle (P = 0.0177, vehicle vs Gem/Carbo combination; P = 0.0065, vehicle vs gemcitabine; P = 0.138, vehicle vs carboplatin). b UCC19 received a combination of Gem/Carbo at recurrence followed by gemcitabine alone and demonstrates stable disease by RECIST criteria off treatment for 15 months. The corresponding PDX model was highly sensitive to Gem/Carbo (P < 0.0001). c UCC17 (MSI-H) received 4 cycles of neoadjuvant gemcitabine/cisplatin. The patient’s radiographic response was minimal (stable disease by RECIST criteria) and there was no pathological response (pT3 disease at RNU). Minimal tumor growth inhibition was observed with Gemcitabine/Cisplatin in the corresponding PDX (P = 0.07). Two-way ANOVA test (Prism) was used for statistical analysis without adjustment. Data are presented as mean values ± SD (standard deviation). Source data for preclinical studies are provided as a Source Data file.